{"links":{"html":"https://www.erudio.com/reports/rasolve-301-nct06881784","json":"https://www.erudio.com/reports/rasolve-301-nct06881784.json","markdown":"https://www.erudio.com/reports/rasolve-301-nct06881784.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rasolve-301-06881784"}},"request":"https://www.erudio.com/contact?report=rasolve-301-06881784"},"offer":{"cited_commentary_sources":24,"verified_hcp_statements":97,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rasolve-301-nct06881784"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rasolve-301-06881784","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rasolve-301-nct06881784","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:08:20.897233Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":9,"title":"Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)"},{"claim_count":10,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":9,"title":"Primary endpoint: Overall survival (OS) in the RAS G12X-C population"},{"claim_count":16,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":16,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":25,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":9,"title":"Dose optimization and the interpretation of 200 mg"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":5,"title":"Post-G12C-inhibitor sequencing, CNS activity and resistance"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":4,"title":"Clinical meaning of active-state, multi-selective RAS targeting"},{"claim_count":20,"coverage":"discussed","id":"A4","source_count":5,"title":"Credibility and generalizability of the early-phase subgroup"},{"claim_count":10,"coverage":"discussed","id":"A5","source_count":2,"title":"Patient support, rash prevention and sustained treatment"},{"claim_count":8,"coverage":"discussed","id":"A6","source_count":4,"title":"Local trial availability, guideline reporting and regulatory access"},{"claim_count":3,"coverage":"discussed","id":"A7","source_count":3,"title":"Combination rationale versus regimen-specific clinical evidence"}],"counts":{"cited_sources":24,"claims_by_expression_type":{"comparison":4,"interpretation":28,"opinion":16,"question":13,"restatement":17,"uncertainty":2,"unspecified":17},"claims_by_kind":{"source_observation":97},"clinician_statements":13,"evidence_units":103,"findings":7,"organisational_accounts":7,"people_cited":11,"people_identity_verified":9,"people_total":11,"screened_sources":36,"verified_claims":97},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":3,"views":8},"has_counterview":true,"limitations":2,"links":{"context":1,"support":15},"ma_question":true,"named_voices":7,"passages":13,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Optimism remains conditional on clearing the docetaxel evidence threshold"},{"id":"F2","structure":{"claims":23,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":5,"views":13},"has_counterview":true,"limitations":3,"links":{"context":1,"support":27},"ma_question":true,"named_voices":8,"passages":25,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"The safety debate depends on attribution, population and the burden of staying on treatment"},{"id":"F3","structure":{"claims":29,"claims_by_group":{"comparisons":0,"experience":0,"questions":7,"restated":14,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":36},"ma_question":true,"named_voices":9,"passages":34,"sources":12,"sources_by_kind":{"commentary":11,"media":1}},"title":"The most clinically attractive subgroup is also the focus of methodological skepticism"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":5},"has_counterview":false,"limitations":2,"links":{"context":1,"support":14},"ma_question":true,"named_voices":7,"passages":13,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"The 200 mg choice is interpreted as dose optimization rather than maximal dosing"},{"id":"F5","structure":{"claims":19,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":2,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":24},"ma_question":true,"named_voices":9,"passages":20,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Broader RAS targeting generates enthusiasm but leaves subtype, CNS and sequencing questions open"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":11,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Trial access, guideline reporting and approval must remain separate messages"},{"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Combination enthusiasm is largely relayed rationale, not established NSCLC combination evidence"}],"medical_affairs_question":"Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Optimism remains conditional on clearing the docetaxel evidence threshold"},{"id":"section-2","level":2,"title":"Safety depends on attribution, patient burden and the ability to continue"},{"id":"section-3","level":2,"title":"The attractive subgroup remains vulnerable to selection and comparison problems"},{"id":"section-4","level":2,"title":"Dose choice is interpreted as optimization, not a contest for the highest dose"},{"id":"section-5","level":2,"title":"Breadth beyond G12C creates selection and sequencing questions"},{"id":"section-6","level":2,"title":"Access messages need indication, geography and timing attached"},{"id":"section-7","level":2,"title":"Combination interest is attributed rationale, not a regimen recommendation"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":3}],"id":"T1","label":"Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":2}],"id":"T2","label":"Primary endpoint: Overall survival (OS) in the RAS G12X-C population"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":12},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":4},{"id":"F7","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":13}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":10},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":21},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":6},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:08:20.897233Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T06:30:41Z","record_hash":"0f419e7d8678b58aed79fa6dbb9f22b0c57ecc0bb822f10bf2713fd19461af44","release_hash":"7342ec228c58be7f15a80f5b0fe06a86eaf85b87a88a5dad36f7bd28cd685c20","report_id":"erudio-nct06881784","run_id":"2488323d-ae1d-4f12-82b1-03b33e13f099","schema_version":"5.0","slug":"rasolve-301-06881784","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on RASolve 301 in the sources reviewed for this edition leads to one open question: Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve? Its leading findings: (1) optimism remains conditional on clearing the docetaxel evidence threshold. (2) the safety debate depends on attribution, population and the burden of staying on treatment. (3) the most clinically attractive subgroup is also the focus of methodological skepticism. 4 more findings follow. 36 sources screened, 24 cited; not all HCPs or all public discussion.","meta_description":"36 sources screened · 97 verified statements (13 from clinicians verified by NPI or staff page) from 24 sources · 7 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T06:30:41Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":36},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on antitumor activity and dose-dependent response in previously treated RAS-mutant non-small cell lung cancer.","Not yet captured in this edition: a view on the evidence needed to validate daraxonrasib’s response signal in previously treated advanced RAS-mutant NSCLC.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The discussion summarized here does not establish the prevalence of any view among HCPs. Social posts, repeated material and third-party relays cannot be counted as independent clinician endorsements.","Some potentially relevant posts and video passages were not fully assessed. Discussion using different names, spellings or no trial name may be underrepresented.","No protocol or results publication for NCT06881784 was available. The efficacy and safety results discussed by the authors are earlier-phase findings, not RASolve 301 outcomes.","The identity of several public authors is unverified, and some clinical roles or displayed credentials are not confirmed. The educational video cannot be attributed to named HCPs.","Official regulatory and guideline documents were not available to confirm the reported approval, guideline and reimbursement statements. Those statements remain attributed to their sources and dates.","Early efficacy, durability, safety and discontinuation figures differ in population, dose or definition across sources. The report does not harmonize them into a common dataset or resolve numerical inconsistencies.","Post dates do not independently establish presentation or readout dates, changing opinions or disagreement across clinical settings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":24},"count":24,"evidence_window":{"end":"2026-10-13","start":"2025-03-27"},"retrieval_snapshot":"2026-10-29T00:18:16.821937Z","timeline":[{"count":2,"week":"2025-W13"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W32"},{"count":15,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06881784:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06881784:context","quote_policy":"short_quote_link_out"},{"id":"openfda:13a65923-d072-4dac-8620-8eabbf8c3641:20260827","quote_policy":"short_quote_link_out"},{"id":"openfda:2992d633-08fa-44f3-b14d-41700f24686b:20260415","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fw72jnkx2y52rwe3jfugamhc-3mvuuisz4qs27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3lp4xv6s3ut2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lpbzms2vvv2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pko5fzgbs5p5upqhkrv5w7vt-3llemh6x3ds24","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501138296916303872","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501390441888788480","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501533474324017152","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7515774867493830657","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905277113466274048:667bb892-4ff9-4827-b485-76b72af7b66c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945111957381529777:6f3f9c0b-f9ae-49d8-8a0f-2e7eec4052ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979013848251429000:72b31d43-e244-4d72-8e8b-a595507d010f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2002462881548300433:6ce7f58c-f466-4121-af58-5325345bba7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045639402542801216:9bb737c4-9e4a-4fb2-94be-2cfe7dba71d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045973283951009985:5c03c2e6-ab2f-4543-be56-1ac50c7fce98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086166912141287520:06ef7c37-3892-4470-8a06-cbec85ddcff7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087397809779839046:9182e8b4-b64f-4cea-b5b4-f41e1b6a945b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094488798465802550:91d094af-f248-4901-a1f3-2a8a0fd761e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095270078560293153:1793efa1-3c15-46a5-ac96-49ee2fd5ef83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095279644916519007:21d44e37-64e6-4f73-a390-cb7c7aecedcb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095279827607789755:3ef8c20e-7e4a-4b22-b461-e48c3007726b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095283912645718198:4e7485b9-45c3-4425-8a30-43a5f7f16a4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095329245992018300:cf832dcf-f371-4ee2-b8ee-37d647209442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095363813239361739:2730f1fe-d263-4249-a27a-85ff3f5038fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095436792770281765:0d0b1d93-77d3-4b66-b516-b0eb140bef52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095437032130756677:a2a627b0-1111-468c-b19b-a5273c345de4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095511158111567924:b6ae17cd-638d-4e47-833f-1ba0736c8485","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095527237772886154:433f87c9-8e13-4a95-841c-be98f7009abe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095543111212528092:66505b96-2148-4baf-8bd4-61cfa0f680c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095785089263116297:bb9f2cd1-f1a2-402b-ae5a-a1a34fb37f27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095946590569607210:991a2967-6e33-4d54-b388-c6cf0b670350","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096252812111810945:fbae8545-c7a0-4e01-a09f-d49a12e46890","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099554434347147266:18c06df8-4b67-4fbc-9a3e-8655f33dc7c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102013294282158352:53254425-caa0-4e8c-8480-9786c45c3f73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102729703018918351:2a5c8e92-54ea-41f7-a65d-d496ca04f5aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103869620394557742:29936c21-2048-453b-b473-f1b8391a088a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WSTrTem-e74","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":36},"count":36,"evidence_window":{"end":"2026-10-13","start":"2025-03-27"},"retrieval_snapshot":"2026-10-29T00:18:16.821937Z","timeline":[{"count":2,"week":"2025-W13"},{"count":2,"week":"2025-W20"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W51"},{"count":2,"week":"2026-W16"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":18,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":2,"week":"2026-W38"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: daraxonrasib","status":"unmapped"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"reason":"Unmapped registry condition: NSCLC (Non-small Cell Lung Cancer)","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: NSCLC","status":"unmapped"},{"reason":"Unmapped registry condition: NSCLC (Non-small Cell Lung Carcinoma)","status":"unmapped"},{"reason":"Unmapped registry condition: NSCLC (Advanced Non-small Cell Lung Cancer)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RASolve 301","aliases":["RASolve 301","Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC"],"brief_title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Cancer","NSCLC","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC (Advanced Non-small Cell Lung Cancer)"],"enrollment":{"count":590,"type":"ESTIMATED"},"interventions":[{"name":"daraxonrasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06881784","official_title":"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.","measure":"Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)","timeFrame":"Up to approximately 4 years"},{"description":"OS is defined as the time from randomization until death from any cause.","measure":"Overall survival (OS) in the RAS G12X-C population","timeFrame":"Up to approximately 4 years"}],"registry_last_updated":"2026-09-29","registry_url":"https://clinicaltrials.gov/study/NCT06881784","short_name":"RASolve 301","short_name_basis":"registry_acronym","sponsor":"Revolution Medicines, Inc.","start_date":{"date":"2025-05-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"RMC-6236-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}